KR20240001136A - IgE 항체를 포함하는 조성물 - Google Patents

IgE 항체를 포함하는 조성물 Download PDF

Info

Publication number
KR20240001136A
KR20240001136A KR1020237035816A KR20237035816A KR20240001136A KR 20240001136 A KR20240001136 A KR 20240001136A KR 1020237035816 A KR1020237035816 A KR 1020237035816A KR 20237035816 A KR20237035816 A KR 20237035816A KR 20240001136 A KR20240001136 A KR 20240001136A
Authority
KR
South Korea
Prior art keywords
antibody
ige
subject
frα
ige antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237035816A
Other languages
English (en)
Korean (ko)
Inventor
제임스 스파이서
소피아 카라기안니스
Original Assignee
킹스칼리지런던
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/060749 external-priority patent/WO2021214329A1/en
Priority claimed from GBGB2109550.0A external-priority patent/GB202109550D0/en
Application filed by 킹스칼리지런던 filed Critical 킹스칼리지런던
Publication of KR20240001136A publication Critical patent/KR20240001136A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020237035816A 2021-04-23 2022-04-22 IgE 항체를 포함하는 조성물 Pending KR20240001136A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2021/060749 WO2021214329A1 (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody
EPPCT/EP2021/060749 2021-04-23
GBGB2109550.0A GB202109550D0 (en) 2021-07-01 2021-07-01 Composition
GB2109550.0 2021-07-01
PCT/EP2022/060693 WO2022223784A1 (en) 2021-04-23 2022-04-22 Composition comprising an ige antibody

Publications (1)

Publication Number Publication Date
KR20240001136A true KR20240001136A (ko) 2024-01-03

Family

ID=81750377

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237035816A Pending KR20240001136A (ko) 2021-04-23 2022-04-22 IgE 항체를 포함하는 조성물

Country Status (10)

Country Link
US (1) US20240190955A1 (https=)
EP (1) EP4326770A1 (https=)
JP (1) JP2024514935A (https=)
KR (1) KR20240001136A (https=)
AU (1) AU2022263376A1 (https=)
BR (1) BR112023021873A2 (https=)
CA (1) CA3215850A1 (https=)
MX (1) MX2023012557A (https=)
WO (1) WO2022223784A1 (https=)
ZA (1) ZA202309456B (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CA2848842C (en) 2011-10-04 2020-09-29 King's College London Ige anti -hmw-maa antibody
RU2019141270A (ru) 2017-05-16 2021-06-16 Иммуноджен, Инк. Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител
GB202006093D0 (en) * 2020-04-24 2020-06-10 King S College London Composition

Also Published As

Publication number Publication date
EP4326770A1 (en) 2024-02-28
AU2022263376A9 (en) 2023-11-30
MX2023012557A (es) 2023-11-08
CA3215850A1 (en) 2022-10-27
WO2022223784A1 (en) 2022-10-27
AU2022263376A1 (en) 2023-11-23
JP2024514935A (ja) 2024-04-03
ZA202309456B (en) 2025-03-26
BR112023021873A2 (pt) 2023-12-19
US20240190955A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
CN114829402B (zh) 抗ror1抗体及其制备方法与应用
EP3604338A1 (en) Anti-ox40 antibody and use thereof
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
EP4223777A1 (en) Anti-cd3 antibody and uses thereof
CN112739716A (zh) 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
TW202031686A (zh) 抗ｃｄ７９ｂ抗體、其抗原結合片段及其醫藥用途
CN114269783A (zh) 结合egfrviii的单克隆抗体及其应用
CN113045659B (zh) 抗cd73人源化抗体
US20250082771A1 (en) Dosage regimen of an anti-cdh6 antibody-drug conjugate
CN115991784A (zh) 抗cd47-cldn18.2双特异性抗体及其用途
US20240190955A1 (en) Composition comprising an ige antibody
CN117203237A (zh) 包含IgE抗体的组合物
WO2026069561A1 (en) Anti-cd147 antibodies and methods of using the same
TWI855692B (zh) 抗cd200r1抗體
WO2025131054A1 (en) Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
US20250276077A1 (en) Epha2 antibodies
AU2024308265A1 (en) Anti-her2 antibody for use in treating a low her2 expressing tumor in a subject
KR20230006824A (ko) Ige 항체를 포함하는 조성물
WO2022255248A1 (ja) 抗ｃｄ２６抗体と免疫チェックポイント阻害剤との併用療法
CN120189525A (zh) 靶向b7-h3和trop2的抗体-药物偶联物及其用途
CN117715654A (zh) 包含抗-cd205抗体和免疫检查点抑制剂的药物组合
EA052759B1 (ru) Антитела против pd-l1 и конъюгаты антитело-лекарственное средство
HK40052936A (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231019

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250407

Comment text: Request for Examination of Application